Almost all major causes of ill-health and premature death in human societies worldwide -including cancer, cardiovascular disease, diabetes and many infectious diseases -are, at least in part, genetically determined. Typically, risk of succumbing to one of these illnesses is thought to depend on both the individual repertoire of variation within a number of key susceptibility genes and the history of exposure to relevant environmental factors. For many of these conditions, the molecular basis of disease pathogenesis remains obscure. This represents a major obstacle to development of improved, rational strategies for disease treatment, prevention and eradication. It is easy therefore to appreciate the importance attached to efforts to deliver more comprehensive understanding of the molecular basis of disease pathogenesis. Nor is it hard to understand that identification of major susceptibility genes should highlight those components of molecular machinery that are critical for the preservation of normal health.
The challenge of gene discovery in multifactorial diseases
In the past decade, gene identification for monogenic (or Mendelian) diseases has become an increasingly routine affair. Causative variants for several hundred different single-gene disorders have been pinpointed (Peltonen & McKusick 2001) , and these have, in many cases, provided profound insights into fundamental biological processes. However, single-gene disorders are, by their very nature, relatively rare, and whilst the impact of the genomic variants responsible may be severe for those individuals (and families) affected, collectively they account for only a small proportion of illness within the population.
In contrast, we can expect the genetic variants that influence susceptibility to the dominant causes of morbidity and mortality in societiesfor example, cardiovascular disease, diabetes, cancer -to have more modest effects at the individual level, but to have substantial impact within populations (Lander & Schork 1994 , Vyse & Todd 1996 . This distinction goes to the heart of the challenge presented by multifactorial traits. The variants that need to be identified are likely: to be common; to be present in both affected and unaffected individuals; to be associated with relatively modest increases in individual risk; to have subtle rather than disastrous effects on gene product function (e.g. via alterations in transcriptional regulation); and to interact in complex, non-linear ways with other susceptibility factors contributing to disease (both genetic and environmental).
One way of looking at this distinction between monogenic and multifactorial traits is in terms of the correspondence between genotype and phenotype. Characteristically, for monogenic traits, this correspondence is close to 1:1. Thus, all individuals with cystic fibrosis have defective function of the cystic fibrosis transmembrane conductance regulator protein (CFTR) due to mutations in both copies of the CFTR gene, and all individuals with two severe mutations in CFTR inevitably develop cystic fibrosis (although genetic and environmental modifiers can vary the precise phenotypic expression) (Kiesewetter et al. 1993) . In complex traits, this genotype-phenotype correspondence is much less tight. For one thing, the same phenotype may arise as a result of abnormalities in any one of (or combination of) several genes ('genetic heterogeneity'), or even, in certain circumstances from environmental exposures alone ('phenocopies'). For another, variation at any given site will not provide precise prediction of an individual's disease status ('incomplete penetrance'). A given variant may increase the individual risk of a given disease phenotype, but even this risk may be heavily dependent on the genetic and environmental context ('gene-gene' and 'gene-environment interaction').
If this were not demanding enough, multifactorial traits present additional complexities. First, there are often difficulties with diagnostic classification (e.g. what glucose level constitutes 'diabetes' (World Health Organisation Study Group 1985) ?). How can one differentiate lateonset type 1 diabetes (T1D) from type 2 diabetes (T2D) (Tuomi et al. 1993) ? Secondly, ascertainment of the family material, which is the basic substrate for most genetic research, may be problematical, especially in diseases of late-onset (Frayling et al. 1999) . Thirdly, the assessment of the candidacy of particular genes and pathways is frustrated by ignorance of the biological basis of disease. (Is T2D primarily a disease of carbohydrate or lipid metabolism? Is the beta-cell, muscle, fat, liver or brain 'culpable' (Aitman et al. 1999) ?) Fourthly, there may be marked ethnic heterogeneity -if Neel's 'thrifty genotype' explanation for the high prevalence of diabetes and obesity is correct (Neel 1982) , it may well be that different ethnic groups have developed diverse molecular mechanisms to provide the metabolic efficiency that maximises survival during periods of erratic food supply (but which predisposes to obesity and diabetes in times of plenty).
Thus, whilst many of the tools employed in the dissection of complex traits are similar to those developed for, and successfully implemented in, studies of monogenic traits, there are necessarily substantial differences, both qualitative and quantitative, in the strategies adopted.
Tools of the trade
The analytical tools of the complex-trait mapper are based around the detection of signals for linkage and linkage disequilibrium (LD), and it is worth trying to disentangle these two related but distinct concepts.
Linkage
The independent segregation of chromosomes during meiosis ensures that alleles at two genes on different chromosomes are distributed randomly to gametes (the genes are 'unlinked'). However, when two genes lie on the same chromosome, their relationship following chromosomal segregation is determined by recombination between homologous chromosomes occurring during meiosis. The closer the physical location of the two genes, the less likely it is that a recombination event will separate them, and the more likely it is that alleles at those genes will be observed to co-segregate (into gametes, and thereby into offspring). This genetic 'linkage' provides a powerful tool for disease gene localisation (Ott 1999) . All one needs, in principle, is a sufficiently large collection of families segregating the disease of interest (and hence assumed to be segregating the susceptibility genes for which one is searching), and a set of polymorphic markers, at known chromosomal locations, which can be typed to reveal patterns of chromosomal segregation in those pedigrees. Linkage analysis represents the computational tool which allows identification of those genomic regions which show statistically significant co-segregation with disease and are therefore likely to be harbouring susceptibility loci. Whilst ready access to large pedigrees, and a simple, defined genetic architecture, have made linkage analysis the central tool for gene localisation in monogenic traits, precisely the same approaches are applicable, with some modification, to complex traits. The principal modifications include: (i) an emphasis on analysis of large numbers of small (nuclear) families or sibships rather than small numbers of large pedigrees (Davies et al. 1994 , Lander & Schork 1994 ; (ii) use of 'non-parametric' model-free methods which do not require explicit description of the genetic architecture of the trait (Kruglyak et al. 1996) , something scarcely possible for multifactorial diseases (Ott 1990) ; and (iii) ability to capitalise on underlying disease-related quantitative trait data (e.g. measures of insulin sensitivity for T2D) to complement analysis of dichotomous disease traits and, in many circumstances, offer increased power (Ghosh & Schork 1996 . Even so, as described below, the modest relative risks expected of most complex trait susceptibility loci set real limits to the reliable and robust detection of the linkage signals they may produce.
Linkage disequilibrium
Whilst linkage analysis looks at the effects of recombination events on the segregation of genes within families, LD analysis deals with the patterns of alleles within populations. LD is a special case of 'allelic association', that is characterised by the co-occurrence on a given chromosome of two alleles (from different loci) at a frequency different from that expected from the product of their individual frequencies (Lander & Schork 1994) . For example, in European populations, the T allele at the 23 HphI polymorphism within the insulin gene, and the cluster of so-called class III alleles at the nearby INS-VNTR minisatellite are each present on about 30% of chromosomes (Bennett & Todd 1996) . However, because of tight LD in the region, the frequency with which chromosomes carry both alleles is also 30% rather than the 9%, the product of their individual allele frequencies, that one would expect if they were in equilibrium (Fig. 1) . The cardinal feature of LD, as opposed to simple allelic association, is that the two loci concerned are linked. Other mechanisms, such as latent population substructure, which can lead to associations between alleles at unlinked loci (i.e. association without LD), are troublesome from a methodological point of view, but are not generally of any great intrinsic biological interest (Lander & Schork 1994 .
To appreciate the ways in which linkage and LD analyses are deployed in the hunt for complex trait genes, it is important to understand a little more about the processes governing the development and dissipation of LD. LD around an allele arises, in the first place, either through natural selection or as a result of events and processes modifying the genetic composition of a population during its history; these include periods of small population size ('bottlenecks'), genetic admixture (due to interbreeding with a distinct population) and stochastic effects ('genetic drift'). At the same time, any LD established is gradually dissipated by the actions of recombination and mutation (Kruglyak 1999 , Reich et al. 2001 .
The most readily understood scenario for the generation of LD is provided by the 'founder effect'. Consider a modern population which arose through expansion of a small group of original founders (Finland or Tristan da Cunha are oft-quoted examples). Imagine that one of those founders carried a genetic variant that increases susceptibility to a given disease (but without a severe impact on reproductive potential). As that variant is passed down through subsequent generations, successive recombination events will mean that the descendent chromosomes on which that variant is carried become increasingly fragmented patchworks, reflecting those diverse parental and ancestral contributions. However, (very) close to the variant itself, the opportunities for such disruptive recombination events will have been limited, and many of the chromosomes carrying the variant will still resemble the original founding chromosome (and therefore each other). The consequence is a localised 'patch' where alleles on the ancestral chromosome are associated with (and in LD with) disease. Since chromosomes that carry the susceptibility variant will be overrepresented amongst those with disease, it should be possible to find this patch by comparing disease cases and controls from the present-day population, and searching for regions where alleles show significant associations with disease.
Since it is underpinned by the same relationship between physical distance and recombination frequency, LD, just like linkage, can be used to localise susceptibility genes ( Jorde 1995 ( Jorde , 2000 . However, because any residual LD will have 'survived' the attrition of recombination events throughout a population's history, LD signals are less extensive than those arising from linkage studies (of the order of a few tens of kilobases, rather than a few tens of megabases) and, in principle, capable of providing much more precise localisation of disease genes (Lonjou et al. 1999 , Abecasis et al. 2001 , Reich et al. 2001 . The main drawback in using LD to map genes is that the genomic extent, pattern and magnitude of LD in any given mapping situation (as defined by the combination of variant, disease and population ; 'filled' alleles predominate (70%) at both loci. Assume that the loci are close neighbours on the same chromosome such that 'haplotypes' (comprising the alleles on a given chromosome) can be constructed. Clearly, there are four possible haplotypes, as shown in the lower part of the diagram. The relative proportions of those four haplotypes will be determined by the extent of LD between the two loci. If loci A and B are in linkage equilibrium (left panel), the haplotype frequencies are simply the products of the allele frequencies, and knowing an individual's genotype at locus A will provide no clues to their genotype at locus B. Alternatively, if (as in the other panels) loci A and B are in LD, haplotype frequencies will depart from this expectation, and certain haplotypes (right panel) may be absent or rare. Knowledge of an individual's genotype at locus A will provide some (middle panel) or complete (right panel) knowledge of the genotype at locus B. studied) is dependent on a range of highly variable and unpredictable factors, including population history, evolutionary selection, disease architecture and mutation rates (Risch 2000 , Roses 2000 , Weiss & Terwilliger 2000 . Thus, the power and value of LD analysis in any given complex trait mapping effort is hard to gauge in advance. LD studies have certainly proven useful for disease gene localisation and identification in rare monogenic diseases in both population isolates and outbred populations (e.g. cystic fibrosis (Kerem et al. 1989) ). The detection of association is the objective of most candidate gene studies for complex traits (Altshuler et al. 2000a ), but in this case, the scale of the task is eased by the expectation that one might be detecting the actual aetiological variants (so that the degree of local LD is less of an issue). There are some promising examples of how LD can succeed in the more challenging task of localising complex trait genes within large genomic regions (Bennett & Todd 1996 , Roses 2000 , Hugot et al. 2001 . However, substantial theoretical, methodological and practical obstacles remain to be overcome before one can become confident about the prospects for genome-wide analyses for LD (analogous to the genome-wide scans for linkage which are now routine) (Risch & Merikangas 1996 , Weiss & Terwilliger 2000 .
Strategies for gene discovery in multifactorial traits
Candidate gene studies Conceptually, the simplest strategy for gene discovery in multifactorial traits is the 'candidate gene study' (Altshuler et al. 2000a . The usual procedure is to select a gene, usually on the basis of its known or presumed biological function, and the hypothesised relevance of that function to the disease of interest, and then to look for association between one or more variants in that gene and the disease phenotype. If a robust, statistically significant association is found, the implication is that the variant tested is either contributing directly to the phenotype or else is in LD with (and therefore relatively close to) such a variant. There are, of course, a number of alternative explanations including the possibility that the association is entirely spurious (due to type 1 error (Altshuler et al. 2000a) ) or that the association has been the result of latent population stratification, through, for example, failure to match cases and control groups for ethnic background. This can result in non-linked genes appearing associated, i.e. association without LD (Williams et al. 1981 , Lander & Schork 1994 . Family-based association methods (using parent-offspring trios or discordant sibling pairs) are a popular means of controlling for this second possibility, since their merit lies in generating a set of control chromosomes matched for parental origin to the disease chromosomes , Boehnke & Langefeld 1998 . The transmission disequilibrium test (TDT) has been the most widely applied of these family-based association tests, and in its simplest form involves measuring the frequency with which a given variant is transmitted from heterozygous parents to their offspring. Clearly, in normal circumstances, one would expect both alleles in a heterozygous parent to have an equal chance of being represented in their gametes, and subsequently in their offspring. Finding that a variant is significantly overtransmitted from heterozygous parents to affected offspring (in a set of parent-offspring trios ascertained for disease, for example) provides a simultaneous test of both association and linkage, which will not be deceived by association resulting from latent stratification. The TDT also provides an excellent tool for detecting parent-of-origin effects (Huxtable et al. 2000) .
The T2D genetics literature is not unique in being populated by multiple association studies of candidate genes (McCarthy & Hitman 1993) . Many positive associations have been reported but subsequent replication has proven the exception rather than the rule (Altshuler et al. 2000a ). This confusing state of affairs is a consequence, in part, of the intrinsic 'biological' difficulties associated with complex trait genetics -the individual effect of any given variant is likely to be modest and to depend on genetic background and environmental exposure . However, this has undoubtedly been compounded by inadequacies in experimental method (small sample sizes; multiple testing leading to inflated type 1 error; publication bias; unrepresentative control populations).
Two examples amply illustrate the problem. Keavney et al. (2000) conducted a meta-analysis of published association studies relating ACE (the gene for angiotensin-converting enzyme) I/D genotype to risk of myocardial infarction. Whilst the combined risk ratio for the 'at-risk' DD genotype in 35 published small studies (total of 3578 cases) was 1·57 (99% confidence interval: 1·38-1·78), the equivalent figures for 15 larger studies (11 492 cases) was 1·02 (0·95-1·11). Clearly, publication (and other) biases had produced a significant overestimation of effect in the smaller, less powerful studies. Altshuler et al. (2000a) recently evaluated the PPARG Pro12 Ala variant in T2D. They convincingly demonstrated a modest but highly significant increase in relative risk (1·25, P=0·002) associated with the common Pro allele in analysis of several large Europid data sets. They also showed that this risk ratio estimate was fully consistent with all previously published data on this variant, even though most of those previous -smaller -studies had reported no association (presumably due to type 2 error).
These, and other studies, have led to a concerted re-evaluation of the principles of candidate gene association studies in multifactorial disease and the promulgation of improved, more exacting 'industry standards' designed to deliver more robust results (Editorial 1999 , Altshuler et al. 2000a . These include the need for: (i) significantly increased sample sizes (thousands of subjects, even more if gene-gene and geneenvironment interactions are to be detected); (ii) incorporation of diverse study designs including case-control, family-based association studies and intermediate phenotype data sets, given the particular strengths and weaknesses of each approach ; (iii) replication of findings in additional study groups of similar ethnic origin, and the exploitation of data sets from disparate ethnicities to unravel complex LD relationships between variants (Horikawa et al. 2000) ; (iv) an increasing emphasis on 'gene-wide' analyses including a full inventory of perigenic variation and comprehensive evaluation of association with disease, especially if the aim is definitive 'exclusion' of a gene from disease involvement; and (v) functional assessment of presumed aetiological variants, e.g. through in vitro or transgenic assays, to provide biological substantiation of statistical findings.
To date, very few studies of candidate genes for complex trait loci come close to approaching these requirements, leaving a slew of previous reports of association 'in limbo'. Examples from the T2D literature include associations with the genes for insulin (Bennett & Todd 1996 , Huxtable et al. 2000 , the sulphonylurea receptor (Inoue et al. 1996 , Hani et al. 1998 , 't Hart et al. 1999 ) and insulin receptor substrate 1 (Almind et al. 1993 , Clausen et al. 1995 , Hitman et al. 1995 . A re-evaluation of some of these 'classic' candidates is therefore opportune. Crucially, the same experimental standards must be observed for all candidate genes, however they come to attention, including those defined initially on positional grounds (see below), and those arising out of more sophisticated and comprehensive assessments of biological candidacy, through expression profiling and proteomics, for example.
Analyses of animal and human models of disease
Given the intrinsic difficulties associated with a direct assault on the complex multifactorial traits themselves, one attractive strategy is to focus on more genetically tractable 'models' of those diseases, on the basis that genes identified in these models will provide clues to pathways implicated in the commoner, multifactorial forms of human disease. There are the following three main study options.
Study of monogenic forms of disease
Apposite examples include the analysis of maturityonset diabetes of the young (MODY), an autosomal dominant, early-onset form of T2D (Hattersley et al. 1992 ) and the identification of single-gene effects underlying early-onset obesity (Montague et al. 1997 ). In the case of MODY, a combination of classical Mendelian linkage-based positional cloning approaches, and candidate gene studies, have revealed at least five different genes responsible for severe pancreatic beta-cell dysfunction and consequent diabetes (the genes for glucokinase (Froguel et al. 1992 , Hattersley et al. 1992 , hepatocyte-nuclear factors 1 (Yamagata et al. 1996a ), 4 (Yamagata et al. 1996b ) and 1 (Horikawa et al. 1997) , and insulin promoter factor-1 (IPF1) (Stoffers et al. 1997) ). These studies have provided valuable insights into the molecular circuitry of the beta-cell. With the exception of IPF1, where mutations in the coding regions can, depending on the severity of functional impairment, result in either MODY or an increased predisposition to multifactorial T2D (Stoffers et al. 1998 , Hani et al. 1999 , MacFarlane et al. 1999 , these particular genes do not seem to play a significant role in the later-onset forms of T2D. In the second example, identification of families segregating severe early-onset obesity due to mutations in the genes for leptin (Montague et al. 1997) , the leptin receptor (Clément et al. 1998) , the melanocortin-4 receptor (Vaisse et al. 1998 , Yeo et al. 1998 , Farooqi et al. 2000 and proopiomelanocortin (Krude et al. 1998) have confirmed the physiological role of these molecules in the control of energy balance in man.
Study of syndromic forms of disease
Common traits are sometimes observed as components within larger monogenic disease syndromes, e.g. T2D in partial lipodystrophy (Shackleton et al. 2000) or Friedreich's ataxia (Ristow et al. 1998) ; obesity in Bardet-Biedl syndrome (Katsanis et al. 2000) . Gene identification for the syndrome (generally amenable to standard 'Mendelian' positional cloning methods) is clearly relevant to efforts to understand the pathogenesis of the associated complex trait.
Study of animal models of disease
Genetic dissection of relevant animal models is facilitated by a variety of factors, including large litter size, short generation times, capacity to engineer crosses and generate congenic lines and the ability to control environmental co-factors. Selective breeding, gene-targeting strategies and mutagenesis programmes have made available a wide range of rodent models for many diseases (Brown & Nolan 1998) . In the T2D field, genetic dissection of polygenic models such as the Goto-Kakizaki (GK) rat is likely to be particularly relevant to human disease (Galli et al. 1996 , Gauguier et al. 1996 . At least seven loci controlling T2D-related subphenotypes have been identified in this model, revealing complex relationships between genotype and phenotype (for example, different loci influence fasting and post-load glycaemia) (Galli et al. 1996 , Gauguier et al. 1996 . At least one of these loci (Nidd/gk2) corresponds to a region implicated in human T2D susceptibility (chromosome 1q24) (Hanson et al. 1998 , Elbein et al. 1999 , Vionnet et al. 2000 , Wiltshire et al. 2001 .
Positional cloning in multifactorial disease
All the approaches described above rely on implicit assumptions. For candidate genes studies, the assumption is that the major genes influencing susceptibility to the disease of interest act in known biological pathways. For model-based approaches, the expectation is that findings from human and/or animal models of disease will be relevant to the multifactorial forms of disease. Although both assertions are perfectly reasonable, positional cloning methods, applied directly to families segregating multifactorial forms of disease, provide a means to progress gene discovery that is not hamstrung by such prior assumptions.
The objectives here are to apply linkage to define, then LD-based approaches to refine, disease-gene location. Although, in principle, it is a strength of such analyses that they can proceed without reference to the biology of the disease itself or to gene function, in practice, an assessment of the biological candidacy of the genes mapping into a region of interest defined by linkage is an important component of the strategy (the label 'positional candidate' analysis neatly describes this integration of positional and biological information (Collins 1995)).
Lessons from T1D
Theoretical difficulties inherent in undertaking such studies in multifactorial traits have been outlined above and are amply reinforced by data emerging from studies of the two main forms of diabetes. Although both T1D and T2D show strong familial aggregation, the extent of the familial clustering differs. The sibling relative risk ( s : the ratio of the risk of disease in the sibling of an affected individual compared with the population risk (Risch 1990 )) for T1D in Europeans populations is of the order of 15 (6% risk in siblings: 0·4% in the population), but only 3·5 for T2D (35 vs 10%) (Köbberling & Tillil 1982 , Vyse & Todd 1996 . Since this index of familiarity sets an upper limit on the combined effect of all susceptibility genes (plus any component of shared family environment), the power of linkage approaches was always likely to be greater for T1D than T2D (for equivalent sample size).
Indeed, the first successful applications of genome-wide linkage analysis to a complex multifactorial trait were described in T1D (Davies et al. 1994 , Hashimoto et al. 1994 . Because of the complex segregation patterns typical of multifactorial traits, the approach taken (and closely followed for many other complex traits) was based around the analysis of large numbers of affected sibling pairs (Fig. 2) . Non-parametric (modelindependent) linkage methods were used (Kruglyak et al. 1996) to identify those chromosomal regions where siblings sharing disease showed greater genetic similarity than expected by chance (Fig. 3) .
These studies identified one very clear signal, around the HLA region on chromosome 6, accounting for about 40% of the inherited component of disease susceptibility. This result was not a surprise given the strong existing evidence for association between HLA alleles and T1D, but did provide a powerful validation of the methodology. The initial study (Davies et al. 1994 ) also threw up a number (around ten) of lesser signals, several of which have now been confirmed in other genome scans in T1D families (Concannon et al. 1998 , Mein et al. 1998 . Two of the regions contain strong candidate genes -those for INS, the gene for insulin, on chromosome 11p (Bennett & Todd 1996) and CTLA4 on chromosome 2q (Marron et al. 1997 ) -which association studies have shown are both clearly implicated in disease susceptibility. Efforts continue to identify susceptibility genes underlying some of the other linkage signals, and to fill in the remaining pieces of the molecular puzzle. The picture emerging from these genetic studies neatly coincides with our evolving understanding of T1D pathogenesis, identifying variation in genes responsible for the regulation of the immune response to beta-cell antigens (HLA and CTLA4) or the level of thymic expression of those antigens (INS) as key determinants of inherited susceptibility to disease (Todd 1999) .
T2D: a tougher target
The relatively low s for T2D was always going to make it a tougher 'nut' to crack, and not surprisingly, success in gene identification has been slower to arrive. One reason has been the inevitable delay associated with ascertainment of the many hundreds of families required to compensate for the modest relative risks expected of any individual T2D susceptibility locus. Several large genome-wide scans for linkage have been completed for T2D in recent years, in a wide variety of populations, the largest in Pima Indians (Hanson et al. 1998) , Finns (Mahtani et al. 1996 , Ghosh et al. 2000 , Watanabe et al. 2000 , French (Vionnet et al. 2000) , British (Wiltshire et al. 2001) , Ashkenazim (Permutt et al. 2001) and MexicanAmerican (Hanis et al. 1996 , Duggirala et al. 1999 pedigrees. The one absolutely clear conclusion from these results is that there is no single locus for T2D of major global significance equivalent to the contribution made by HLA to T1D susceptibility. However, as more data from these scans become public, it is reassuring to observe certain chromosomal regions emerging repeatedly; the most promising replicated signals are those on chromosomes 1, 12 and 20 (Ehm et al. 2000) . For example, a 30 cM region centred on chromosome 1q24 has shown evidence for linkage to T2D in published data from Pima Indians (Hanson et al. 1998) , French (Vionnet et al. 2000) and Utah Mormon (Elbein et al. 1999 ) studies, and is also replicated in the large UK 'Warren 2' study (573 affected sibpair families) (Wiltshire et al. 2001 ). As described above, further support for this locus is derived from the mapping of a diabetessusceptibility locus to the equivalent region in the GK rat (Galli et al. 1996 , Gauguier et al. 1996 . This example also illustrates the important point that the evidence supporting the candidacy of a region often comes from various different sources and that, whilst guidelines for interpretation of linkage studies are essential (Lander & Kruglyak 1995) , the case for a given region cannot always be distilled into a single significance value.
Clearly, in the face of the relatively modest signals for linkage expected in the analysis of multifactorial traits, replication of this kind can provide an important means of distinguishing those Figure 3 Principle behind non-parametric linkage analysis for a complex trait. The chromosome illustrated harbours a disease susceptibility gene at the position marked. A chromosome-wide scan has been performed on a set of T2D sibpairs. The result of that scan is summarised by an allele-sharing statistic (providing a measure of the percentage allele-sharing (identity by descent) at each point along the chromosome) which is shown above. At some distance from the susceptibility gene, siblings sharing disease are no more similar in terms of genotype than chance expectation and the allele-sharing statistic is close to 50% (stochastic variation means that it will vary around this level). However, near the gene of interest, siblings correlated for disease also show a correlation of their genotypes, reflecting the fact that they are more likely to have co-inherited a susceptibility allele from one (or both) parents. The peak of excess allele-sharing provides the clue that a susceptibility gene lies in the vicinity.
peaks which are 'real' (i.e. harbouring susceptibility loci) from those likely to be 'spurious' (reflecting stochastic variation in the linkage statistic) (Lander & Kruglyak 1995) . Nevertheless, it is important to appreciate the limitations of replication. There are several valid reasons why a real locus may prove hard to replicate, including ethnic heterogeneity (a locus may be more important in one particular population (Horikawa et al. 2000) ), differences in diagnostic criteria or ascertainment scheme (McCarthy et al. 1998) , and the effects of random variation on the power to detect a locus (Suarez et al. 1994) .
There are several useful statistical tools which, by allowing more comprehensive examination of available data, should assist in this vital discrimination between real and spurious signals. These include stratification analyses, which, by reanalysing genotype data after stratification for relevant intermediate traits (e.g. age of disease onset, obesity), aim to minimise any loss of power associated with genetic heterogeneity (Merette et al. 1992 , Watanabe et al. 1999 . Conditional analyses, which set out to allow explicitly for the oligogenic aetiology of complex traits by seeking statistically significant (and therefore, by inference, biologically significant) interactions between regions of interest identified on genome scans, can also provide support for the biological relevance of regions showing evidence for linkage (Cox et al. 1999 , Leal & Ott 2000 . Finally, the development of muchimproved computational and statistical methods for the analysis of continuous phenotypes in large pedigrees has facilitated a direct assault on the genetic dissection of those intermediate traits (for example, insulin sensitivity and beta-cell function in the case of T2D) considered to underlie the development of the dichotomous disease phenotype , Duggirala et al. 1999 . Through application of these methods, it should be possible to increase confidence that a given region emerging from a genome scan truly harbours a susceptibility gene, and that further positional cloning efforts are justified.
The post-genomic scan challenge
This 'locus validation' process represents only the initial step in gene discovery. The regions arising from a typical multifactorial trait genome scan are large (10-30 cM) and the peak of linkage in most cases provides only an approximate indication of the position of the susceptibility gene (Kruglyak & Lander 1995 , Roberts et al. 1999 . Whilst in Mendelian disease it is generally possible to narrow the critical region by typing additional meioses (if available), this is a highly inefficient procedure in complex traits, where the poor correlation between genotype and phenotype means that any individual recombination event carries only limited (statistical) information on the location of the disease gene.
The researcher aiming to positionally clone a complex trait gene is therefore faced typically with the daunting task of addressing a region of approximately 20 cM, likely to contain 20 million bases, and 200 or more genes. This region will contain about 60 000 common variants (mostly single-nucleotide polymorphisms (SNPs)) of which up to 1000 will be in coding sequence, and as many as another 15 000-20 000 in sequences potentially relevant to gene function and regulation (introns, untranslated regions, promoters, remote regulatory regions). The task of identifying the single variant (or set of variants) that confers susceptibility remains a major endeavour.
Essentially, there are two complementary, interrelated approaches that are currently applicable. The prospects for both have been very significantly enhanced by access to the increasingly complete human genome sequence (International Human Genome Sequencing Consortium 2001) and related efforts to annotate that sequence to identify the location of expressed sequences (Birney et al. 2001 , Shoemaker et al. 2001 ) and common sites of human variation (The International SNP Map Working Group 2001).
The first approach relies on LD mapping to improve localisation within the region of linkage. As described earlier, the fact that LD extends only a relatively short distance (tens of kilobases is a reasonable estimate for outbred populations) from the susceptibility locus should mean that LD is capable of reducing substantially the interval of interest (Lonjou et al. 1999 , Abecasis et al. 2001 , Reich et al. 2001 . Having said that, the highly unpredictable pattern and extent of LD in any given situation means that any systematic search across a large genomic region is likely to require a very high density of markers (arguably, at least one every 10 kb) and, because the effect sizes to be detected are modest, rather large sample sizes (hundreds, even thousands, of subjects) (Kruglyak 1999 , Roses 2000 , Weiss & Terwilliger 2000 . Whilst the markers are now available, with several million SNPs catalogued in public and proprietary databases (The International SNP Map Working Group 2001), these prestigious genotyping requirements remain prohibitive with current technology on both economic and logistical grounds. Three developments are likely to ease the situation in the medium term. The first is the development of more robust, less-expensive, high-throughput methods for SNP typing (Kwok 2000) . The second is the development and validation of methods for deriving reliable estimates of allele frequencies from pooled DNA samples, which, if successful, will reduce substantially the amount of genotyping involved in surveying a region for LD , Germer et al. 2000 . The third, and a little way further in the future, is the elucidation and dissemination of genome-wide 'haplotype maps', providing access to the 'baseline terrain' of LD in any given region (and population) and thereby enhancing efforts to pick up departures from that baseline in samples of disease chromosomes (Service et al. 2001) .
The complement to such 'indirect' LD mapping approaches to gene identification concentrates more on the detailed evaluation of the strongest positional candidates in the region of interest. The first step in such an analysis involves retrieval of as complete as possible a list of the genes within the region. Fortunately, the improving annotation of the draft human sequence is capable of delivering increasingly complete transcript inventories (Birney et al. 2001) . Even so, the number of genes in a typical region of linkage (hundreds) is likely to be too large to contemplate analysing all of them for variation and association with disease, making some sort of prioritisation desirable to arrive at a 'shortlist' of the most promising positional candidates. Such a shortlist needs to match the known and presumed function of the various regional transcripts and their patterns of tissue expression to the researcher's knowledge of the disease of interest. The data informing this process may be derived from the burgeoning genomics databases (e.g. ENSEMBL, www.ensembl.org) and/or from inhouse laboratory analyses (for example, determining the qualitative and quantitative expression profiles of regional candidates by interrogating a regional cDNA microarray with message from tissues of interest (Aitman et al. 1999 , Ugolini et al. 1999 , Shoemaker et al. 2001 ).
Characterising candidate genes
Once a strong positional candidate has been identified, the final common pathway is welltravelled and essentially the same as the analysis of any candidate gene (see above). Relevant parts of the gene need to be resequenced to compile an inventory of genomic variation, and the variants uncovered tested for association with disease. Ideally, such studies should employ a combination of case-control and family-based association tests (Editorial 1999 .
Several important considerations need to be emphasised. First, it seems likely that variants involved in complex trait susceptibility will often be acting through effects on transcriptional regulation and/or RNA stability (rather than through altered primary and secondary amino acid structure). Any comprehensive gene survey therefore needs to include 'unfashionable real estate' including untranslated regions, all intronic sequence and (given poor characterisation thus far of critical regulatory regions) a considerable stretch of upstream sequence. Secondly, the vagaries of LD mean that involvement of a gene in disease susceptibility cannot be excluded simply because a subset of variants in that gene show no association with disease; systematic and comprehensive analyses of variation in multiple populations are required. Thirdly, susceptibility may often be governed by the combined action of several different variants within a gene (each, for example, having a cumulative effect on transcriptional activity or RNA stability). Several likely examples of this exist including the calpain-10 gene (CAPN10) in T2D (Horikawa et al. 2000) ; and insulin (INS) (Bennett & Todd 1996 , Stead et al. 2000 and HLA in T1D (Zavattari et al. 2001) . Such complex intra-locus interactions certainly complicate interpretation of association data. Finally, the genetic architecture of complex traits remains uncertain. If the 'common disease, common variant' hypothesis holds up (Cargill et al. 1999 , The International SNP Map Working Group 2001 , this should mean that the extent of allelic heterogeneity is relatively modest, and facilitates both the LD mapping and the consequent functional characterisation of candidate variants. If, instead, allelic heterogeneity is more widespread, and susceptibility to a given trait more often determined by multiple, diverse, lowfrequency susceptibility alleles (Pritchard 2001 ), LD will be harder to find, and confirming the functional relevance of any single variant more problematical (Todd 2001) .
Recent successes in positional cloning
It might be tempting to conclude from the above that the prospects for successful gene identification by positional cloning in complex traits are poor. Recent successes in both T2D (Horikawa et al. 2000 , Roses et al. 2000 and Crohn's disease (Hugot et al. 2001 , Ogura et al. 2001 ) strongly suggest otherwise, and demonstrate the ways in which the approaches described above have been successfully applied to gene discovery. Hanis et al. (1996) reported their genome scan on 258 Mexican-American sibships, which provided significant evidence of linkage to T2D around the marker D2S125 on chromosome 2q (designated NIDDM1). Attempts to replicate this finding in other ethnic groups were mostly unsuccessful (Hani et al. 1997 , Ghosh et al. 1998 . However, using the conditional analysis methods alluded to above, independent support for NIDDM1 was obtained by demonstrating significant interaction between NIDDM1 and a second region on chromosome 15 which had produced a modest signal in the original genome scan (Cox et al. 1999) . This observation clearly required both regions to be having some biological effect on disease susceptibility. These conditional analyses also helped to refine the 'confidence interval' of NIDDM1 to around 2 Mb (equivalent to 7 cM in this telomeric location). At this point, the team switched to an LD-based approach (Horikawa et al. 2000) , identifying SNPs in the region and testing them for association with T2D. Some initial hints of LD focused their attention on a 66 kb region containing three genes, and this was targeted for exhaustive variant detection and further association analyses. A variant in intron 3 of the calpain-10 gene (UCSNP-43) emerged with the best statistical credentials from these analyses; it had the strongest association, and it successfully partitioned the evidence for linkage in the original scan. There were, however, three concerns about this SNP (Altshuler et al. 2000b) . First, it was intronic and did not appear to influence splicing. Secondly, homozygotes for the at-risk allele at UCSNP-43 were, rather surprisingly, not at increased risk. Thirdly, the at-risk allele was highly prevalent (75%) and could not, in isolation, explain the size of the linkage signal. Could it be that other SNPs were contributing to the susceptibility effect? Haplotype studies within CAPN10 in Mexican-American and other European populations (Horikawa et al. 2000) suggest that this is indeed the case, and that individual risk is best described by the individual configuration of alleles at a number of variant sites within the gene.
Final confirmation that these CAPN10 variants are functional will require biological rather than statistical enquiry, for example, through examination of calpain-10 (tissue-specific) knockout mice. Such biological verification should expunge any residual claims that the true aetiological variant lies, undiscovered, elsewhere in the region, its signal being detectable at CAPN10 due to extensive LD relationships across chromosome 2q (Altshuler et al. 2000b ). These functional studies should also start to address the subsequent question: how is that variation in this ubiquitously expressed protease influences risk of diabetes?
Another triumph of the approaches described, outside the metabolic arena, has been the identification of variants in the NOD2 gene as the basis for the region of linkage to Crohn's disease previously identified on chromosome 16 (IBD1). Interestingly, the two groups that reported this finding (Hugot et al. 2001 , Ogura et al. 2001 used rather different approaches to arrive at this discovery, corresponding in fact, to the two main strategies described earlier (Todd 2001) . One group (Hugot et al. 2001) adopted a strategy based on indirect LD mapping. This allowed them (rather serendipitously, it must be said) to localise the susceptibility gene to a much smaller region and directed their focus towards the small subset of genes it contained, NOD2 amongst them. The other successful group (Ogura et al. 2001) embarked on a positional candidate approach and moved directly to a detailed analysis of NOD2 as soon as data emerged supporting its biological candidacy in the disease of interest.
What does the future hold?
There is no doubt, looking back on the last decade, that most efforts to map complex trait susceptibility genes have been fuelled by a heady mix of optimism and a rather unsophisticated attitude to the complexities of multifactorial disease. Quite simply, tools which were proving increasingly successful at delivering gene identification in monogenic diseases were not up to the task of scaling the more demanding heights of complex trait gene discovery. This deficit is now clearly being remedied by a host of technical and biological advances, availability of (as yet, incomplete) annotated human sequence being perhaps the most spectacular example. The recent clatter of complex trait genes identified using the approaches described promises to herald a new wave of success in understanding these major diseases.
What further advances can we expect to expedite and support these future successes? First, improved methods for defining biological candidacy and in the analysis of complex biological systems will undoubtedly speed positional candidate selection and advance efforts to characterise disease pathogenesis once susceptibility genes are found. These analyses will depend on the capacity to conduct global ('genome-wide') analyses at various levels of cellular and organismal organisation -including the transcriptome, proteome and metabonomeand the ability to integrate these disparate information sources (Vidal 2001) . Secondly, the field needs more powerful (technical and statistical) tools for LD mapping in large populations. These should allow researchers to extract more of the information contained in population resources. Given the relatively low power of linkage approaches within families, there is no doubt that LD analyses will be required to take over where linkage alone is likely to fail, in localising signals within large genomic regions, and/or detecting genes of lesser effect (Risch & Merikangas 1996) . Ultimately, these advances may permit genomewide scans for LD to become practicable. At the same time, we need improved statistical tools for determining which variants within a tract of associated polymorphisms are most likely to be functional. Finally, we need access to very large, well-characterised populations so that genegene and gene-environment interactions can be explored with the necessary rigour and power. This will provide the most complete, integrated view of the factors determining disease risk and pathogenesis, and their interactions, and lay the platform for the robust specification of individual risk profile and prognosis, the latter clearly a pre-requisite for future efforts to develop personalised health care
With these and other advances we can expect the next decade to see many more complex traits yield their secrets to the gene mappers.
